[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Boston Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":671},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,132,0,25,[9,48,79,98,115,137,160,188,227,261,283,310,338,364,390,424,454,485,506,538,556,588,608,628,649],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100468419","teg-use-in-children-undergoing-procedures-with-high-anticipated-blood-loss-100468419",false,"NCT05379530","TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss","Thromboelastography (TEG) and Intraoperative Coagulation Management of Pediatric Patients Undergoing Procedures With High Anticipated Blood Loss","Inclusion Criteria:\n\n* Pediatric patients undergoing non-cardiac surgery at BCH with a high likelihood of blood transfusion. Specifically these are defined as a surgery with greater than 25% likelihood of transfusion of any non-albumin blood product.\n* Eligible surgeries include:\n* spinal surgery\n* laparotomy\n* liver transplant\n* craniofacial surgery\n* esophageal atresia\n* craniotomy\u002Fhemispherectomy\n* major abdominal surgery\n* major hip surgery\n* major plastic surgery\n\nExclusion Criteria:\n\n* Patients undergoing cardiac surgery or ECMO cannulation, as these surgeries are generally considered outside the scope of general pediatric surgery.\n* Patients presenting for emergent surgery\n* Patients undergoing surgeries off hours (between 8pm and 8 am), when TEG analysis is unobtainable",true,"ALL","20 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The research team proposes a prospective, observational study to better understand how TEG can be useful in guiding clinical practice in the Main OR for subject's undergoing high transfusion risk surgeries.\n\nIntraoperatively, transfusion of blood products is frequently required to restore oxygen carrying capacity, perfusion and improve coagulation. Both under and over transfusion pose significant risks, particularly to pediatric patients with small starting intravascular volumes. Thromboelastography (TEG) is a validated method of dynamically assessing intraoperative coagulopathy via functional assay. However, while FDA approved and widely used in the adult setting, TEG is not commonly utilized in the setting of bleeding pediatric patients.\n\nRecently, TEG has been made available at BCH for clinical purposes and is being used solely in the cardiac surgery setting. The investigators aim to provide TEG data for non-cardiac pediatric surgical cases with a high risk of intraoperative blood loss in order to assess the impact of this tool on intraoperative management.",[28,29,30],"Surgical Blood Loss","Surgical Hemorrhage","Post Operative Hemorrhage",[32,33,34,35],"thromboelastography","blood transfusion","viscoelastic test-guided","massive hemorrhage","NOT_YET_RECRUITING","2026-08-12",{"date":39,"type":40},"2026-08-14","ACTUAL",{"date":42,"type":22},"2027-01-01",{"date":44,"type":22},"2028-12-01",{"name":46,"class":47},"Boston Children's Hospital","OTHER",{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100616304","phase-4-the-use-of-high-bile-binding-foods-to-reduce-upper-gastrointestinal-bile-acid-concentrations-aim-2-100616304","NCT07303868","The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 2)","Pediatric patients ages 5 to 21 in the randomized arm Inclusion criteria\n\n* receive at least 80% of their nutritional needs via gastrostomy\n* receive blenderized feeds or will start receiving blenderized feeds\n* have no known allergies to ingredients in blenderized feeds;\n* receive their bolus feeds within 30 minutes or less\n* can receive their feeds by syringe push Exclusion criteria\n* have undergone anti-reflux surgery\n* receive post-pyloric feeds\n* are allergic to any component of the administered diets\n* cannot receive their gastrostomy feeds over 30 minutes\n* require a feeding pump for feed administration (as the H-BBB is too thick for pump administration).\n\nPediatric patients ages 5 to 21 in the observational arm Inclusion\n\n* receive at least 80% of their nutritional needs via gastrostomy\n* are taking an amino acid formula\n* have not undergone antireflux surgery Exclusion\n* have undergone anti-reflux surgery\n* receive post-pyloric feeds\n* are not receiving an amino acid-based formula.","5 Years","21 Years",{"count":58,"type":22},66,[60],"PHASE4","Using a four-week randomized, crossover study design, we will assess the impact of 2 weeks of a high bile acid-binding blenderized diet, compared to 2 weeks of a low bile acid-binding blenderized diet, on gastric and salivary bile acid concentrations within individual participants. Four weeks of an amino acid formula will be a comparator group.",[63,64,65],"Feeding Difficulties","Gastrostomy","Aspiration",[67,68,69,70],"blenderized","bile acid","gastrostomy","aspiration","2026-07-31",{"date":73,"type":40},"2026-08-03",{"date":75,"type":22},"2026-10",{"date":77,"type":22},"2030-08",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":96,"locationsCount":97},"100616294","phase-4-the-use-of-high-bile-binding-foods-to-reduce-upper-gastrointestinal-bile-acid-concentrations-aim-1-100616294","NCT07303738","The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 1)","Inclusion Criteria:\n\n* receive at least 80% of their nutritional needs by gastrostomy\n* receive either an amino acid-based formula, an International Dysphagia Diet Standardization Initiative level 4 commercial blend, or a home blend\n* can receive bolus feeds of 240 cc within 30 minutes or less\n\nExclusion Criteria:\n\n* have received a fundoplication\n* receive post-pyloric feeds\n* require medication\u002Fflush administration during the four-hour study period\n* are allergic to any component of the study diets.\n\nTo participate in this study, if patients are taking acid suppression or motility medications (e.g., erythromycin, azithromycin, prucalopride), they will need to stop these at least 72 hours prior to participation in this aim.",{"count":21,"type":22},[60],"We will perform an acute physiology study comparing three different diets-an amino acid-based formula, a low bile acid-binding blenderized diet, or a high bile acid-binding blenderized diet administered through gastrostomy tube. We will determine the differences in gastric and salivary bile acid concentrations between participants over the 4 hour post-prandial timeframe.\n\nParticipants who regularly receive an amino acid-based formula will receive an amino acid-based formula during the study and participants who regularly receive a blenderized feed will receive a blenderized feed during the study. Only participants who regularly receive blenderized feeds will be randomized to receive either the high or low bile acid binding blenderized feed.",[63,65,64],[67,68,69,70],"RECRUITING",{"date":73,"type":40},{"date":94,"type":40},"2025-12-01",{"date":77,"type":22},{"name":46,"class":47},1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":114,"locationsCount":4},"100586303","the-use-of-high-bile-binding-foods-to-reduce-upper-gastrointestinal-bile-acid-concentrations-aim-3-100586303","NCT06913621","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 3)","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 3)","Inclusion Criteria:\n\n* receive at least 80% of their nutritional needs via gastrostomy\n* receive an International Dysphagia Diet Standardization Initiative level 4 commercial blend, home blend or amino acid-based formula\n* receive their bolus feeds within 30 minutes or less.\n\nExclusion Criteria:\n\n* have undergone anti-reflux surger\n* receive post-pyloric feeds\n* receive regular daily prophylactic antibiotics.",{"count":106,"type":22},138,"OBSERVATIONAL","Using a longitudinal cohort design, we will compare the impact of a high BA-binding blenderized diet compared to a low BA-binding blenderized diet and an amino acid-based formula, on gastrointestinal and pulmonary hospitalization and emergency room visit rates over six months.",[63,64,65],[67,68,69,70],{"date":73,"type":40},{"date":75,"type":22},{"date":77,"type":22},{"name":46,"class":47},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":97},"100474242","phase-4-gastrointestinal-dysmotility-on-aspiration-risk-100474242","NCT05455359","Gastrointestinal Dysmotility on Aspiration Risk","The Impact of Upper Gastrointestinal Dysmotility on Aspiration-associated Symptoms","Inclusion Criteria:\n\n1. are 5-21 years of age;\n2. receive \\>90% of their calories by enteral tube (i.e., patients take no food or drink by mouth);\n3. are determined to be at high risk for aspiration pneumonia based on evidence of impaired airway protective mechanisms, documented by aspiration on video fluoroscopic swallow study;\n4. have static neurologic impairment, defined as functional and\u002For intellectual impairment that results from a chronic neurologic or related diagnosis (e.g., cerebral palsy) with no prospect of progression for at least one year;\n5. have chronic respiratory symptoms, defined as coughing, choking, or need for oral suctioning a minimum of three times per week during the prior four weeks.\n\n   \\-\n\nExclusion Criteria:\n\n1. have progressive neurologic impairment;\n2. have a history of prior intact Nissen fundoplication;\n3. are currently taking oral or inhaled antibiotics, including prophylactic antibiotics;\n4. are currently taking or have taken in the last four weeks acid suppression (H2 antagonist or PPI); or\n5. are fed by gastrojejunostomy rather than by gastrostomy. -",{"count":123,"type":22},120,[60],"The hypothesis of this study is that esophageal and gastric dysmotility increase the risk of developing aspiration-associated symptoms in children with neurologic impairment. The investigators are conducting a ten week cross over study comparing prucalopride to famotidine for the treatment of aspiration-associated symptoms.",[127,128,129,130],"Esophageal Motility Disorders","Gastric Motor Dysfunction","Aspiration Pneumonia","Gastro Esophageal Reflux",{"date":73,"type":40},{"date":133,"type":40},"2025-02-13",{"date":135,"type":22},"2027-05-31",{"name":46,"class":47},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},"100326501","a-90-day-phase-3open-labeled-exploratory-study-of-relizorb-100326501","NCT03530852","A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB","A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition","Inclusion Criteria:\n\n1. Male or female patients, ages 2 years to 18 years, inclusive.\n2. Diagnosed with SBS, as determined by medical history and PN dependence (i.e. need for PN for \\>60 days after intestinal resection or a bowel length \\\u003C25% of expected).\n3. Congenital or acquired gastrointestinal disease requiring surgical intervention that has occurred at least 3 months prior to screening.\n4. Patient is on parenteral lipid and at least 30% of daily caloric and fluid intake has been provided by PN for a least 6 months prior to screening\n5. Stable PN nutrition requirement, determined by less than 5% reduction in PN nutrition calories for at least 1 month prior to screening, or at the discretion of the investigator.\n6. The patient has a Central Venous Catheter (CVC) at the time of study inclusion.\n7. Screening direct bilirubin that is in the normal range for age and is not determined to be clinically significant by the investigator.\n8. The patient has an existing feeding tube, receiving enteral nutrition via an enteral feeding pump at a rate\\>10ml\u002Fhr but \\\u003C400 ml\u002Fhr, and is able to tolerate at least 10 ml\u002Fkg\u002Fday enteral nutrition with which the RELiZORB cartridge can be used. The patient can be on bolus or continuous feeds and can use up to 6 cartridges per day for feeding.\n9. Stable enteral nutrition requirement with no change in formula composition or rate for at least 1 month prior to screening.\n10. The parent or legal guardian of the patient is able to read, understand, and is willing to provide informed consent (and assent, if applicable).\n11. The patient (if assent is applicable) or parent or legal guardian of the patient is able to understand the requirements of the study and is willing to bring the patient to all clinic visits and complete all study related procedures (as determined by the investigator).\n12. A parent or legal guardian is willing to provide written authorization for the use and disclosure of protected health information.\n\nExclusion criteria:\n\n1. Other causes of chronic liver disease other than SBS (i.e., hepatitis C, cystic fibrosis, biliary atresia, alpha 1 anti-trypsin deficiency, and Alagille syndrome).\n2. The patient has had a bowel lengthening procedure, including but not limited to, a STEP procedure.\n3. Any serum triglyceride concentration \\>400 mg\u002FdL at screening.\n4. Pancreatic insufficiency as defined as the use of pancreatic enzymes within 30 days prior to screening.\n5. Evidence of untreated intestinal obstruction or active stenosis, as determined by the investigator.\n6. Unstable absorption due to cystic fibrosis or known DNA abnormalities (i.e., familial adenomatous polyposis, Fanconi syndrome) as determined by the investigator.\n7. History of microvillus inclusion disease, as determined by medical history.\n8. Severe known dysmotility syndrome (i.e., pseudo-obstruction, gastroschisis-related motility disorders), as determined by the investigator.\n9. Initiation of teduglutide or other GLP-2 analogues within 6 months of screening\n10. Use of growth hormone, or supplemental glutamine within 3 months prior to screening.\n11. Use of cisapride within 30 days prior to screening.\n12. Active clinically significant pancreatic or biliary disease, as determined by the investigator.\n13. Patients are receiving formulas that are not compatible with the RELiZORB cartridge (example, insoluble fiber-containing formulas)\n14. Determined by the investigator to be unsuitable for participation for any reason.","2 Years","18 Years",{"count":147,"type":22},32,[25],"Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition",[151,152],"Short Bowel Syndrome","Malabsorption",{"date":73,"type":40},{"date":155,"type":40},"2018-11-21",{"date":157,"type":22},"2028-09-30",{"name":46,"class":47},2,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100382761","phase-1-low-dose-il-2-for-the-treatment-of-crohns-disease-100382761","NCT04263831","Low Dose IL-2 for the Treatment of Crohn's Disease","Inclusion Criteria:\n\n1. Age 12-80 years. Maximum age limit for subjects recruited at BCH will be 30 years.\n2. A diagnosis of CD made by standard clinical, radiological, endoscopic and histological criteria.\n\n   a. A subset of patients with Ileostomies or colostomies will be permitted.\n3. Adult subjects with moderate-to-severe CD (CDAI score 220-450)\n\n   a. a modified CDAI will be used to assess patients with ileostomies\u002Fcolostomies. Number of liquid stools per day will be substituted for number of bag empties per day.\n4. Evidence of endoscopic inflammation accessible via ileocolonoscopy or ileoscopy\n\n   1. Simple Endoscopic Score for CD (SES-CD) ≥ 6 or ≥ 4 for isolated ileal disease\n   2. patients with ileostomies will be assessed as patients with isolated ileal disease via SES-CD.\n5. Failure to tolerate or failure to respond to at least one conventional therapy with the intention of inducing or maintaining remission (including but not limited to oral corticosteroids, oral 5-aminosalicylates, azathioprine and\u002For 6-mercaptopurine, TNF alpha antagonist, anti-integrins, ustekinumab). Corticosteroid dependency (inability to taper oral corticosteroids without a recurrence of disease activity) is also included in this category.\n6. Stable doses of concomitant medications, as defined in Section 5\n7. A negative pregnancy test within 2 weeks prior to anticipated commencement of the study drug, in female subjects of child-bearing age. Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.\n8. The ability of adult participants who are able to make their own healthcare decisions to provide informed consent or the ability of a legal guardian to provide consent if the participant is a child (less than 18 years of age) or has mild intellectual disability and cannot consent for him or herself. In the event that a legal guardian provides consent, the study participant must be able to demonstrate an understanding of the study at his or her comprehension level and must have the ability to give verbal assent. If the legal guardian is court appointed, then the legal guardian must be able to provide documentation of court appointed guardianship.\n\nExclusion Criteria:\n\n1. A diagnosis of ulcerative colitis or indeterminate colitis.\n2. Requirement for immediate surgical, endoscopic or radiological intervention for perforation, sepsis, or intra-abdominal or perianal abscess.\n3. History of colorectal cancer or dysplasia.\n4. Positive stool test for Clostridium difficile via GDH\u002FEIA two step testing method. PCR only testing will not be accepted. If patient is GDH positive and EIA negative, enrollment will be permitted.\n5. Current medically significant infection.\n6. Significant laboratory abnormalities;\n\n   1. Hb \\\u003C 7.0 g\u002FdL, WBC \\\u003C 2.5 x 103\u002Fmm3, Plt \\\u003C 50 x 103\u002Fmm3.\n   2. Creatinine ≥ 2x institutional ULN.\n   3. Total bilirubin \\> 2.0 mg\u002FdL, ALT \\> 2x institutional ULN. Elevated unconjugated bilirubin related to Gilbert's syndrome is allowed.\n   4. Abnormal thyroid function tests.\n7. Positive serology for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV).\n8. Positive screening test for tuberculosis (TB).\n9. Treatment with any biologic medication within 4 weeks of first study drug dose (baseline) (see below section on washouts)\n10. Received another IND within 5 half-lives of that agent baseline.\n11. Malignancy within the last 5 years, excluding non-melanoma skin cancer.\n12. Allergy to any component of the study drug.\n13. Pregnant or lactating women.\n14. Inability to comply with the study protocol or inability of the subject or the subject's legal guardian to provide informed consent.\n15. Prior exposure to IL-2.\n16. Uncontrolled cardiac angina or symptomatic congestive cardiac failure (NYHA Class III or IV).","12 Years","80 Years",{"count":169,"type":22},30,[171,172],"PHASE1","PHASE2","The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.",[175],"Crohn Disease",[177,178,179],"Inflammatory bowel disease","Interleukin 2","Regulatory T Cells","2026-07-30",{"date":73,"type":40},{"date":183,"type":40},"2021-03-11",{"date":185,"type":22},"2027-12-30",{"name":46,"class":47},3,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":97},"100610327","phase-1-valproate-for-the-treatment-of-residual-amblyopia-100610327","NCT07226141","Valproate for the Treatment of Residual Amblyopia","VARA","Inclusion Criteria:\n\n1. Age 8-17 years\n2. Amblyopia associated with strabismus and\u002For anisometropia\n\n   * Criteria for strabismus: must meet at least one of the following:\n\n     * Heterotropia at distance and\u002For near with or without spectacle correction\n     * History of strabismus surgery\n     * Documented history of strabismus that is no longer present and felt by the investigator could have caused the amblyopia\n   * Criteria for anisometropia: must meet at least one of the following:\n\n     * ≥ 0.50 D difference in spherical equivalent between eyes\n     * ≥ 1.50 D difference in astigmatism in any meridian between the eyes\n3. Visual acuity measured in each eye within 7 days prior to enrollment using ETDRS protocol on a study certified visual acuity tester as follows:\n\n   * Amblyopic eye visual acuity of 20\u002F40 - 20\u002F400\n   * Sound eye acuity of ≥ 20\u002F25.\n4. Current amblyopia treatment (other than spectacle correction)\n\n   * Subjects actively patching at the time of enrollment screening should continue patching through enrollment\n   * Visual acuity in amblyopic eye has not improved ≥ 1 line (5 letters) by the same testing method from a previous visit ≥ 8 weeks earlier while on treatment\n\n     * Since this determination is a pre-study examination, the method of visual acuity testing is not mandated\n   * Atropine treatment at any time during this pre-enrollment period is not allowed\n   * Any treatment prior to the current patching episode with stable acuity is allowed\n5. Spectacle correction for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction \\\u003C 6 months old:\n\n   • Requirement for spectacle correction:\n   * Spherical equivalent must be within 0.50 D of fully correcting anisometropia\n   * Hyperopia ≥ 3.00 D must be corrected\n   * Hyperopia may not be undercorrected by \\> 1.50 D spherical equivalent and must be symmetrically reduced in each eye\n   * Cylinder power must be within 0.50 D of fully correcting the astigmatism\n   * Cylinder axis must be within 6 degrees of the axis in the spectacles when the cylinder power is ≥ 1.00 D\n   * Myopia of the amblyopic eye \\> 0.50 D spherical equivalent must be corrected\n\n     ◊ Myopia may not be undercorrected by \\> 0.25 D or overcorrected by \\> 0.50D\n\n     • Spectacles meeting the above criteria must be worn:\n   * Until visual acuity in amblyopic eye has not improved ≥ 1 line (5 letters) by the same testing method during 2 consecutive visual acuity measurements at least 4 weeks apart (i.e. minimum of 8 weeks spectacle correction) ◊ Since this determination is a pre-study examination, the method of visual acuity testing is not mandated\n6. Eye examination within 6 months prior to enrollment\n7. Subject must be available for at least 6 months of follow-up, have access to a phone, and be willing to be contacted by clinical staff\n8. By investigator judgment, the subject is likely to comply with prescribed treatment (i.e. no prior history of poor compliance with patching) and unlikely to continue to improve with 2 hours of daily patching alone\n\n2.2.2 Exclusions\n\n1. Myopia \\> -6.00 D spherical equivalent\n2. Presence of associated findings that could cause reduced visual acuity\n\n   • Nystagmus does not exclude the subject if the above visual acuity criteria are met\n3. Previous intraocular or refractive surgery\n4. Strabismus surgery planned within 16 weeks\n5. Current vision therapy or orthoptics\n6. Known past or present liver or kidney disease\n7. Known past or present mitochondrial\u002Fmetabolic disorder\n8. Known past or present psychological problems\n9. Known allergies or contraindications to the use of valproate or anti-epileptic medication\n10. Current use of medication for the treatment of seizures, bipolar disorder, or migraine, or any medication on the appended list of medications that interact with valproate\u002Fvalproate acid and its derivatives which can be found here.\n11. Prior valproate use\n12. Known skin reaction to patch or bandage adhesives\n13. Treatment with topical atropine within the past 12 weeks\n14. Individuals capable of pregnancy who are pregnant, lactating, or may become pregnant within the next 6 months\n\n    * A negative urine pregnancy test will be required for all participants who have experienced menarche at the time of enrollment\n    * Individuals capable of pregnancy must convey an active suitable plan to avoid pregnancy that includes at least one of the following:\n    * Hormonal Contraceptives:\n\n      * Combined oral contraceptives (the pill)\n      * Contraceptive patch\n      * Vaginal contraceptive ring\n      * Progestin-only pills\n      * Hormonal injections (e.g., Depo-Provera)\n      * Hormonal implants (e.g., Nexplanon)\n    * Intrauterine Devices (IUDs):\n\n      * Copper IUD (e.g., ParaGard)\n      * Hormonal IUDs (e.g., Mirena, Skyla, Liletta)\n    * Barrier Methods with Spermicide (less commonly used alone but may be used in combination with other methods for added protection):\n\n      * Male condoms\n      * Female condoms\n      * Diaphragms with spermicide\n      * Cervical caps with spermicide\n    * Sterilization:\n\n      * Tubal ligation (for females)\n      * Vasectomy (Having a partner who has undergone a vasectomy, confirmed by semen analysis)\n    * Abstinence or True Sexual Abstinence:\n\n      o Refraining from heterosexual intercourse\n    * Requirements regarding the establishment of pregnancy status and monitoring for pregnancy over the course of the study may be further defined by the IRB","8 Years","17 Years",{"count":198,"type":22},28,[171,172],"The goal of this clinical trial is to determine the efficacy of valproate as an adjunct therapy to treat amblyopia beyond the critical period in children aged 8-17 years who have amblyopia of ≥3 lines of interocular best-corrected (with glasses) visual acuity difference.\n\nThe main questions it aims to answer are:\n\n* Does valproate enable clinically meaningful and durable visual recovery from amblyopia?\n* Do valproate-treated patients show a change in amblyopic eye visual acuity (lines)? Participants will undergo daily patching for 2 hours (standard of care) plus the addition of valproate or placebo for a total of 16 weeks.",[202,203,204,205],"Amblyopia","Amblyopia Unilateral","Amblyopia, Anisometropic","Amblyopia Strabismic",[202,207,208,209,210,211,212,213,214,215,216,217,218,219],"valproate","valproic acid","pediatric","lazy eye","Histone deacetylase Inhibitor","HDAC","patching","eye patch","visual acuity","visual impairment","critical period","children","ophthalmology","2026-07-29",{"date":180,"type":40},{"date":223,"type":40},"2026-07-01",{"date":225,"type":22},"2027-09-30",{"name":46,"class":47},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":18,"minAge":234,"maxAge":56,"enrollmentInfo":235,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":237,"conditions":238,"keywords":242,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":97},"100647222","observational-data-collection-for-blood-hemoglobin-algorithm-validation-in-pediatrics-100647222","NCT07706140","Observational Data Collection for Blood Hemoglobin Algorithm Validation in Pediatrics","Prospective Observational Data Collection Study for Validation of a Near-Infrared Spectroscopy-Based Blood Hemoglobin Algorithm in Pediatric Patients Undergoing Cardiac Surgery or Cardiac Catheterization","Inclusion Criteria:\n\n1. Age less than 21 years at the time of enrollment.\n2. Scheduled for elective cardiac surgery or elective cardiac catheterization under general anesthesia.\n3. Placement of an arterial catheter as part of routine clinical care for the procedure.\n\nExclusion Criteria:\n\n1. Presence of skin, scalp, or craniofacial abnormalities that prevent proper placement of the near-infrared spectroscopy (NIRS) sensor or may significantly affect measurement quality.\n2. Inability to obtain arterial blood hemoglobin measurements using standard clinical methods.","0 Days",{"count":236,"type":22},100,"This study will enroll children and young adults who are scheduled to undergo planned heart surgery or a heart catheterization procedure while under general anesthesia. Researchers will collect information from a forehead sensor that measures oxygen levels in the body's tissues, along with blood hemoglobin measurements obtained from blood samples that are already being collected as part of routine medical care.\n\nThe goal of the study is to determine whether a blood hemoglobin monitoring method that has already been cleared by the U.S. Food and Drug Administration (FDA) for use in adults may also work well in pediatric patients.",[239,240,241],"Hemoglobin","Cerebral Oxygenation","Congenital Heart Disease",[243,244,245,246,247,248,249,250,251,252],"pediatric cardiac surgery","pediatric cardiac catheterization","transfusion guidance","noninvasive hemoglobin monitoring","near-infrared spectroscopy NIRS monitoring","tissue oximetry","ForeSight system","HemoSphere monitor","algorithm validation","arterial blood gas comparison","2026-07-24",{"date":255,"type":40},"2026-07-27",{"date":257,"type":22},"2026-08",{"date":259,"type":22},"2027-12",{"name":46,"class":47},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":97},"100335921","phase-1-radiation-free-technique-for-evaluating-renal-scarring-rafters-100335921","NCT03653702","Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)","Inclusion Criteria:\n\n* patients older than or equal to 6 months and less than or equal to 35 years old and scheduled for Boston Children's Hospital (BCH) DMSA scan to evaluate renal function and\u002For renal scarring\n\nExclusion Criteria:\n\n* patients with significant congenital renal anatomical abnormalities including horseshoe kidney, kidney malrotation, and multicystic dysplastic kidney (MCDK). Patients with severe cardio-pulmonary diseases will also be excluded.","6 Months","35 Years",{"count":270,"type":22},70,[171],"In this research study the investigators want to study a safe, radiation-free technique known as contrast-enhanced ultrasound that may improve the ability to diagnose or evaluate renal scarring compared to regular ultrasound. This technique requires injection into a vein of a small amount of contrast material called Lumason. Contrast material is a type of dye that helps the investigators image the structures in the body more clearly. If this technique is successful, the need for DMSA studies may be avoided to diagnose or evaluate kidney scarring. DMSA is a more expensive test, causes radiation exposure, may require sedation and\u002For injection of contrast agents with the potential to cause allergic reactions.",[274],"Vesico-Ureteral Reflux","2026-07-20",{"date":277,"type":40},"2026-07-22",{"date":279,"type":22},"2027-07-01",{"date":281,"type":22},"2029-07",{"name":46,"class":47},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":294,"conditions":295,"keywords":299,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":97},"100584583","study-of-an-oral-fluid-testing-approach-100584583","NCT06891235","Study of an Oral Fluid Testing Approach","Oral Fluid Testing to Assess Cannabis Non-Use in Remote Clinical Trials","SOFTA","Inclusion Criteria:\n\n* Age 18 to 30 years\n* Cannabis use on \\>=1x\u002Fweek in the past 30 days\n* Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer)\n* Ability to read and speak English\n* Availability for duration of the study (3-4 weeks).\n* To proceed to oral fluid testing, positive result for urinary TCH-COOH\n\nExclusion Criteria:\n\n• Inability\u002Funwillingness to provide contact information","30 Years",{"count":293,"type":22},200,"The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across \\~3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (\\~Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (\\~Day 21; TLFB interview, urine test, oral fluid test, survey, interview).",[296,297,298],"Cannabis Use","Cannabis Intoxication","Cannabis Use Disorder",[300,301,302],"cannabis use","young adult","oral fluid testing","2026-06-27",{"date":223,"type":40},{"date":306,"type":40},"2025-10-27",{"date":308,"type":22},"2027-05",{"name":46,"class":47},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":317,"maxAge":56,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":326,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":97},"100644761","my01-pressure-monitoring-in-adolescent-tibia-fractures-100644761","NCT07674043","MY01 Pressure Monitoring in Adolescent Tibia Fractures","Continuous Compartment Pressure Monitoring in Adolescent Tibia Fractures","Inclusion Criteria:\n\n* Between the ages of 10 to 21 on the day of surgery\n* Undergoing operative fixation for a fracture of the proximal tibia or tibial shaft\n\nExclusion Criteria:\n\n* Preoperative diagnosis of acute compartment syndrome\n* Preexisting neuromuscular or vascular condition affecting the injured extremity\n* MY01 device malfunction","10 Years",{"count":319,"type":22},50,[25],"The goal of this clinical trial is to learn more about anterior leg compartment pressures in adolescents who have sustained tibia fractures. It will also examine whether measuring anterior compartment pressure helps physicians diagnose acute compartment syndrome (ACS), a rare but dangerous complication that can develop following surgical treatment of a tibia fracture.\n\nThe main questions it aims to answer are:\n\n1. Are there differences in anterior compartment pressures between healthy patients and patients who develop ACS?\n2. Does compartment pressure monitoring aid physicians in accurately diagnosing ACS?\n\nParticipants will have a continuous pressure monitoring sensor placed in their knee anterior knee compartment during their surgery. This sensor will record pressure data following a patient's surgical treatment for 18+ hours.",[323,324,325],"Proximal Tibia Fracture","Tibial Shaft Fracture","Acute Compartment Syndrome",[327,328,329,209],"Tibia fracture","acute compartment syndrome","compartment pressure","2026-06-25",{"date":332,"type":40},"2026-06-29",{"date":334,"type":22},"2026-06-01",{"date":336,"type":22},"2028-06-01",{"name":46,"class":47},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":345,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":97},"100498996","randomized-controlled-crossover-trial-of-postpyloric-feedings-to-improve-pulmonary-outcomes-in-high-risk-preterm-infants-100498996","NCT05777512","Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants","A Randomized Controlled Crossover Trial of Postpyloric Versus Gastric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants","Inclusion Criteria:\n\nPreterm infants born \\\u003C 32 weeks' gestation may enroll at 34-44 weeks post-menstrual age, who:\n\n1. Remain on either invasive ventilation or non-invasive ventilation (continuous positive airway pressure or nasal intermittent positive pressure ventilation) for minimum 48 hours at the time of study entry. The minimum support required for inclusion is CPAP \\> 5cm H2O or CPAP 5 with FiO2 \\> 21%.\n2. Have ongoing need for respiratory support due to underlying lung disease from prematurity.\n3. Are tolerating \\> 80 ml\u002Fkg\u002Fday of enteral feedings at baseline, either via nasogastric (NG) or nasojejunal (NJ) tube. Patients may be receiving gastric (NG) or postpyloric (NJ) feedings.\n\nExclusion Criteria:\n\n1. Infants who are transiently on respiratory support at the time of study entry due to another reason than underlying lung disease from prematurity; for example, recovery from a surgical intervention.\n2. Infants who have other comorbidities that significantly contribute to lung disease, including cyanotic congenital heart disease, or other genetic, congenital, or pulmonary abnormalities.\n3. Infants who were evaluated for necrotizing enterocolitis (including holding feedings) in the 7 days prior to study enrollment.\n4. Infants with known gastrointestinal or airway malformations that would affect tolerance of feeds or the route of delivery of enteral feedings.","0 Hours","1 Year",{"count":319,"type":22},[25],"The purpose of this study is to determine if postpyloric feedings effectively improve objective measures of pulmonary health in preterm infants with chronic lung disease when compared with nasogastric (NG) feedings. This research will (1) determine the optimal nutritional management to prevent a common and costly complication of prematurity, and (2) use a novel crossover design that examines outcomes of clinical endpoints alongside biomarkers.",[351],"Bronchopulmonary Dysplasia",[353,354,355,351,356,357],"Chronic Lung Disease of Prematurity","Postpyloric Feeding","Nasojejunal Feeding","GERD","Gastro-esophageal Reflux",{"date":332,"type":40},{"date":360,"type":40},"2024-04-26",{"date":362,"type":22},"2028-02",{"name":46,"class":47},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":370,"minAge":145,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":372,"conditions":373,"keywords":376,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":387,"leadSponsor":389,"locationsCount":97},"100644854","continuous-wireless-ultrasound-to-monitor-fetal-health-100644854","NCT07676474","Continuous Wireless Ultrasound to Monitor Fetal Health","Inclusion Criteria:\n\n1. Pregnant individual 18 years or older\n2. Singleton uterine pregnancy\n3. Gestational age 20 to 39 gestational weeks\n4. Able to provide written informed consent\n5. Willing to go an single visit lasting 45 minutes - 1 hour including device placement, monitoring and removal\n6. Willing to permit placement of the wireless bioadhesive ultrasound device on their abdomen for approximately 10-30 minutes\n\nExclusion Criteria:\n\n1. Multiple gestation\n2. Maternal abdominal skin condition at the potential site of attachment, such as rash, open wound, etc., preventing placement\n3. Known allergy or hypersensitivity to adhesive material or hydrogel products\n4. Need for urgent clinical management\u002Ftriage\n5. BMI \\> 35, as the signal quality could be impacted by BMI and not the device specifically","FEMALE",{"count":319,"type":22},"This study is a single-center, prospective, and non-randomized feasibility study designed to evaluate the practicality, tolerability, and data quality of short-duration continuous fetal monitoring using a wireless bioadhesive ultrasound device. The study involves a single visit per participant and does not include any therapeutic intervention.\n\nEligible participants will undergo placement of a wireless bioadhesive ultrasound (ABAUS) device on the maternal abdomen for a short-duration monitoring session. The device will acquire continuous or semi-continuous ultrasound data for a total of 10-30 minutes per participant, without altering standard clinical care. The study is observational and is intended to assess the technical feasibility of device placement, the stability of the coupling during routine maternal movement, image quality over time, and the ability to monitor fetal motion, heart rate, and uterine activity using the investigational device under controlled yet realistic clinical conditions.\n\nThe study is non-interventional. No diagnostic or therapeutic decisions will be made based on the ultrasound data collected as part of this research protocol, and all standard prenatal care will proceed independently of participation in this study.",[374,375],"Pregnant Woman With Single Pregnancy","Ultrasound Fetal Medicine",[377,378,379,380,381,382],"Ultrasound","Fetal Ultrasound","Investigational Device","Pregnancy","Singleton","Single pregnancy","2026-06-24",{"date":385,"type":40},"2026-06-30",{"date":385,"type":22},{"date":388,"type":22},"2028-06-30",{"name":46,"class":47},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":17,"sex":18,"minAge":397,"maxAge":56,"enrollmentInfo":398,"targetDuration":55,"studyType":107,"phases":4,"briefSummary":400,"conditions":401,"keywords":408,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":423},"100444723","advanced-spinal-innovations-with-robotics-and-enabling-technology-registry-100444723","NCT05071144","Advanced SPinal Innovations With Robotics and Enabling Technology Registry","ASPIRE","Inclusion Criteria:\n\n* Diagnosis of a spine deformity\n* Scheduled for surgery using robotics and navigation and\u002For patient-specific rods\n* Up to and including 21 years of age\n* Speak and read English or Spanish\n\nExclusion Criteria:\n\n• None","0 Years",{"count":399,"type":22},700,"Creation of a pediatric robotic spine surgery registry will allow for data collection and analysis on the coupled use of robotics and navigation, as well as patient-specific rods in pediatric spine deformity surgery across participating study institutions. Eventually, an educational and informative framework for this technology will be established.",[402,403,404,405,406,407],"Spine Deformity","Idiopathic Scoliosis","Adolescent Idiopathic Scoliosis","Spondylolisthesis","Congenital Scoliosis","Neuromuscular Scoliosis",[409,410,411,412,413,414],"Pediatric","Spine","Surgery","Registry","Robotic","Navigation","2026-06-18",{"date":417,"type":40},"2026-06-22",{"date":419,"type":40},"2021-12-13",{"date":421,"type":22},"2031-12",{"name":46,"class":47},10,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":18,"minAge":431,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":97},"100641724","phase-4-eeg-biomarkers-for-adhd-stimulant-treatment-100641724","NCT07650643","EEG Biomarkers for ADHD Stimulant Treatment","EEG Biomarkers for Pediatric ADHD Treatment Stratification","Inclusion Criteria:\n\n1. Ages 7:0 - 10:11 (years:months)\n2. Has a diagnosis of ADHD or being evaluated for ADHD\n3. Stimulant naïve or previously trialed stimulant medications for \\\u003C 6 months without achieving symptom remission, per caregiver report and\u002For medical chart review (if available)\n4. CGI-Severity rating of 4 \"Moderately ill\" through 6 \"Severely ill.\"\n5. Willing and able to comply with study procedures\n\nExclusion Criteria:\n\n1. Use of stimulants or other psychotropic medications within 7 days before Eligibility Visit\n2. History of severe side effects to stimulants (suicidality, complete loss of appetite, cardiopulmonary complications) per caregiver report or medical chart review, determined by the study MD\n3. Intellectual disability or IQ \\\u003C 75 per medical chart review or performance on standardized cognitive testing during the Eligibility Visit\n4. Diagnosis of Autism spectrum disorder (ASD) per medical chart review or caregiver report\n5. Fetal alcohol exposure per medical chart review or caregiver report\n6. Current suicidal ideation per caregiver or child report on CSSRS\n7. Non-febrile seizures per caregiver report or medical chart review\n8. Cardiopulmonary conditions, pregnancy or other medical conditions that contraindicate psychostimulant use per determination by the study MD","7 Years","11 Years",{"count":434,"type":22},220,[60],"Pediatric attention deficit hyperactivity disorder (ADHD) affects up to 10% of children in the U.S. and more than 90% are prescribed stimulant medications according to clinical guidelines. The standard of care for pharmacological treatment of ADHD is a \"trial-and-error\" approach that requires frequent dose adjustments, side effects management, and communication among doctors, parents, and school personnel over weeks, months, and years. In the first year following prescription of stimulant medications, \\>50% of doctors are not able to conduct the recommended follow-up with their patients. Many patients stop taking medications or keep taking medications that do not work well, as a result.\n\nThis investigation will use a non-invasive brain imaging technique called EEG to look for activity in the brain that can predict which children with ADHD will respond well to two commonly prescribed stimulant medication groups, methylphenidate and amphetamines. Based on a previous study, it is expected that EEG signals can differentiate among children whose ADHD symptoms will get better on methylphenidate, and those whose ADHD symptoms will get better on amphetamines.\n\n220 participants ages 7-11 with ADHD will be enrolled. Participants will not have autism or intellectual disabiltiy. They will not currently be taking psychiatric medications. Participants will not have not taken stimulant medications before or have tried stimulant medications \\>6 months or experienced an improvement in their ADHD symptoms by taking a stimulant medication before.\n\nStudy Participation Includes:\n\n1. Participant and caregiver complete a 3-hour visit at the Arnett Laboratory at 2 Brookline Place. During this visit, participants complete a brief IQ test and an EEG while their caregiver completes questionnaires and a clinical interview. The caregiver will give permission to request survey responses from the participant's teacher.\n2. The next day, the participant and caregiver will come back to the laboratory for a 1-hour visit. The participant will do another EEG while the caregiver fills out more surveys. The doctor will take the participant's vital signs and prescribe the medication.\n3. The participant will be randomly assigned to take either methylphenidate HCl or amphetamines every morning for 3 weeks. At the end of each week, the caregiver and teacher will fill out a questionnaire about the participant's behaviors and symptoms, including side effects.\n4. For one week, the participant will not take medications. They will come back into the lab for another EEG at the end of that week.\n5. The participant will then take the other medication every morning for 3 weeks. At the end of each week, the caregiver and teacher will fill out a questionnaire about the participant's behaviors and symptoms, including side effects.\n6. It will take participants about 7 weeks to complete this study. During this time, they will complete 3 in-person and 6 virtual study visits.\n7. The research funds will cover cost associated with the study. The participant's health insurer will not be billed for the medications or treatment. Medications will be provided through the research pharmacy.\n8. Participants will be given a report at the end of the study with details about the medication trials, symptom response, and any other findings. They will receive up to $270 for the completion of the study. Some travel-related costs will be covered by the study.",[438],"ADHD",[440,441,442,443,438,444,445],"stimulants","EEG","biomarker","randomized crossover","treatment","stratification","2026-06-12",{"date":448,"type":40},"2026-06-16",{"date":450,"type":22},"2026-09-15",{"date":452,"type":22},"2031-08-31",{"name":46,"class":47},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":463,"conditions":464,"keywords":470,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":97},"100095145","genetic-study-of-chronic-prostatitischronic-pelvic-pain-syndrome-cpcpps-100095145","NCT00499317","Genetic Study of Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)","CP\u002FCPPS","Inclusion Criteria:\n\n* Have symptoms for at least 3 months within the preceding 6 months:\n* Pain in the pelvic area\n* Urinary frequency and\u002For\n* Urinary urgency and\u002For\n* Sexual dysfunction (erectile dysfunction)\n* Have CP\u002FCPPS, Interstitial Cystitis (IC), Bladder Pain Syndrome BPS, or Bladder Fasciculation Syndrome (BFS)\n* Be willing to provide a blood\u002Fsaliva, bladder tissue (from previous biopsy) and urine sample\n* Agree to complete several brief questionnaires\n* Family member of someone with CP\u002FCPPS, BPS, IC or BFS\n* Live in the USA or Canada\n\nExclusion Criteria:\n\n* Major structural\u002Fanatomical urinary tract abnormalities\n* Underlying inborn or congenital conditions which affect the urinary tract\n* Surgery\u002Fchemotherapy in the pelvic area\n* Bacterial cause to CP\u002FCPPS or recurrent Urinary tract infections (UTI)\n* Traumatic cause to CP\u002FCPPS",{"count":462,"type":22},500,"Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS) is a condition with several causes of which some remain unknown. It is believed that some types of CP may be genetic or passed down (inherited) from one generation to the next.\n\nIn this study, we are collecting genetic material and medical information to try to determine if genetic factors play a role in CP\u002FCPPS. We will be collecting DNA (from Blood\u002FSaliva sample) and urine from each participant. Bladder tissue from affected individuals will also be collected. Individuals and families with CP\u002FCPPS will be enrolled. Family members of an individual with CP\u002FCPPS are eligible whether or not they also experience CP\u002FCPPS symptoms.",[465,466,467,468,469],"Chronic Prostatitis (CP)","Chronic Pelvic Pain Syndrome (CPPS)","Painful Bladder Syndrome (PBS)","Benign Frequency Syndrome (BFS)","Interstitial Cystitis",[471,472,473,474,475,476],"Urgency","Frequency","Pelvic pain","Sexual dysfunction","Erectile dysfunction","Painful intercourse","2026-06-10",{"date":479,"type":40},"2026-06-11",{"date":481,"type":40},"2007-01-15",{"date":483,"type":22},"2028-12-31",{"name":46,"class":47},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100637846","validation-of-ecg-based-ventricular-arrhythmia-localization-algorithms-in-patients-with-repaired-tetralogy-of-fallot-100637846","NCT07607821","Validation of ECG-Based Ventricular Arrhythmia Localization Algorithms in Patients With Repaired Tetralogy of Fallot","Validation of ECG-Based Ventricular Arrhythmia Localization Algorithms in Patients With Repaired Tetralogy of Fallot: A Prospective Pace Mapping Study","Inclusion Criteria:\n\n* Adult patients \\>\u002F= 18 years with repaired tetralogy of Fallot with pulmonary stenosis scheduled for clinically-indicated diagnostic electrophysiology (EP) study.\n\nExclusion Criteria:\n\n* Dextrocardia or mesocardia.\n* Double outlet right ventricle.\n* Tetralogy of Fallot with pulmonary atresia.\n* Contraindication to femoral arterial access.\n* Mechanical aortic prosthesis.\n* Inability to provide informed consent.",{"count":169,"type":22},[25],"Doctors use patterns on heart rhythm tracings (ECGs) to predict where abnormal heart rhythms originate, but these prediction methods were developed in people with normal heart structure. Patients with repaired Tetralogy of Fallot have hearts that developed differently, and cardiologists do not know if these prediction methods work accurately for them. In this study, the investigators will test whether three commonly used prediction methods work in Tetralogy of Fallot patients by pacing the heart from known locations during an already-scheduled heart procedure and comparing the predicted location to the actual location. Participation adds approximately 15 minutes to the procedure and does not require additional visits. The results will help cardiologists understand whether current methods can be trusted when planning treatments for abnormal heart rhythms in this patient population, or whether new prediction methods need to be developed.",[496,497],"Tetralogy of Fallot (TOF)","Ventricular Tachycardia","2026-06-04",{"date":500,"type":40},"2026-06-05",{"date":502,"type":22},"2026-07",{"date":504,"type":22},"2027-07",{"name":46,"class":47},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":517,"conditions":518,"keywords":528,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":187},"100609745","phase-2-double-blind-trial-of-everolimus-for-improving-social-abilities-in-pten-germline-mutations-100609745","NCT07218575","Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations","A Randomized, Placebo Controlled Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations","Inclusion Criteria:\n\n1. Diagnosis of PTEN Harmartoma Tumor Syndrom (PHTS), confirmed by genetic testing (the testing may be done as part of study screening)\n2. Experiences at least moderate levels of social difficulties, based on SRS T score \\> 60 (measured during screening Have at least a moderate impairment in social abilities, based on SRS score during study screening\n3. Fluent in English\n4. Females of child-bearing potential must have no plans to become pregnant and be using contraception during the study (if sexually active).\n5. Availability of parent, care-giver, partner or other suitable individual who can provide observation reports and provide transportation to attend clinic visits\n6. Adequate liver, kidney and bone-marrow function (checked during screening)\n7. Medically stable\n8. No plans to change school, behavioral therapies, home services or speech therapy during the study period\n9. Ability to swallow medicine in pill form\n\nExclusion Criteria:\n\n1. Ongoing or planned treatment with any medication with known or possible ant-mTOR activity (e.g. sirolimus), or strong inducers or inhibitors of CYP3A, CYP2D6, P450 or PgP (e.g. cyclosporine, ketoconazole, erythromycin, rifampin, phenytoin, phenobarbital) or ACE inhibitors\n2. Chronic treatment with systemic corticosteroids or other immunosuppressive treatments (topical or inhaled corticosteroids are allowed).\n3. Major surgery or any anti-cancer therapies (including radiotherapy) within 4 weeks of enrollment\n4. Neurosurgery within 6 months of enrollment\n5. Uncontrolled diabetes defined as HbA1c \\>8% despite treatment\n6. Uncontrolled hyperlipidemia (defined as fasting serum cholesterol \\> 300 mg\u002FdL OR \\>7.75 mmol\u002FL AND fasting triglycerides \\> 2.5 x ULN, assessed during screening)\n7. History of Hepatitis B, Hepatitis C or HIV\n8. Participation in a clinical trial in the 60 days prior to study entry\n9. Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)\n10. Patients who have a history of another primary malignancy, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from with the patient has been disease free for \\> 3 years","45 Years",{"count":21,"type":22},[172,516],"PHASE3","The goal of this study is to examine the safety and treatment effects of everolimus in adults and children with PTEN Hamartoma Tumor Syndrome (PHTS) who experience social difficulties. The study will measure if everolimus can safely improve social abilities and functioning in this study population.\n\nPTEN Hamartoma Tumor Syndrome (PHTS) is a genetic condition that results from alteration (germline variant) to the PTEN gene. It is associated with a wide range of symptoms and characteristics, which vary from individual to individual. These include symptoms such as harmatomas (non-cancerous lesions), an increased risk of certain types of cancer, having a larger than average head, and abnormalities in blood vessels. Some people also have neurobehavioral problems including social difficulties. It is estimated approximately 25% (1 in 4) of people with PHTS meet the criteria for an autism diagnosis.\n\nThe study lasts for one year. In the first 6 months half of participants will receive everolimus as a once daily oral tablet, and half will receive placebo tablets. For the second 6 months all participants will receive everolimus. Visits to the study clinic are required at the start, month 3, month 6, month 9 and month 12, with phone calls or virtual visits in between. Assessments include questionnaires, blood tests and urine tests, physical and neurological exams, and vital signs.\n\nEverolimus is an existing FDA approved medication used to treat other conditions, including a genetic condition called tuberous sclerosis complex which has some similarities to PHTS, and several types of cancer.",[519,520,521,522,523,524,525,526,527],"Cowden's Disease","Cowden's Syndrome","Lhermitte-Duclos Disease","Cerebellum Dysplastic Gangliocytoma","Bannayan Zonana Syndrome","Myhre Riley Smith Syndrome","Riley Smith Syndrome","PTEN Hamartoma Tumor Syndrome","Bannayan Riley Ruvalcaba Syndrome",[529,530],"PTEN mutation","Autism","2026-06-02",{"date":498,"type":40},{"date":534,"type":22},"2026-09-01",{"date":536,"type":22},"2030-09",{"name":46,"class":47},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":234,"maxAge":346,"enrollmentInfo":544,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":97},"100461185","implementation-of-a-consensus-based-discharge-protocol-for-preterm-infants-with-lung-disease-100461185","NCT05285345","Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease","Inclusion Criteria:\n\n* Preterm infants born \\\u003C32 weeks with at least mild BPD, defined as 28 days of respiratory support after birth.\n* Efforts will be made to include a mix of infants with mild, moderate, and severe BPD, including infants discharged on oxygen.\n\nExclusion Criteria:\n\n* Discharge to a location other than home.\n* Infants with other congenital disease (cardiac, genetic, neurological) thought to contribute significantly to their respiratory disease.",{"count":319,"type":22},"The researchers have worked to create consensus recommendations among national efforts to help with the transition and coordination of care for preterm infants with lung disease around discharge from the neonatal intensive care unit to home. This study looks to evaluate implementation of the recommendations at Boston Children's Hospital and referring NICU's (Beth Israel Deaconess Medical Center and Brigham and Women's Hospital). Specifically, the research team will be looking at follow-up rates, healthcare utilization, and parental satisfaction\u002Ffeedback with implementation of these guidelines.",[351],[351,548],"NICU Discharge","2026-05-31",{"date":531,"type":40},{"date":552,"type":40},"2023-09-27",{"date":554,"type":22},"2027-11",{"name":46,"class":47},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":346,"maxAge":166,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":574,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":97},"100621323","phase-4-propofol-only-versus-dexmedetomidine-propofol-in-children-undergoing-magnetic-resonance-imaging-100621323","NCT07369128","Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging","A Randomized, Dose-Ranging Trial of Propofol-Only and Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging","Inclusion Criteria:\n\n* Patients presenting as outpatients, scheduled to receive an anesthetic for MRI of brain, body (spine, chest, abdomen, and\u002For pelvis) and\u002For extremity (arm and\u002For leg).\n* Patients must be a candidate for the sedation technique described in this study with a natural airway. This decision will be made by a staff member of the Department of Anesthesiology.\n* Between 1 and 12 years of age.\n* ASA status I, II, or III\n\nExclusion Criteria:\n\n* Inpatient at BCH\n* Diagnosis of a difficult airway, severe obstructive sleep apnea that is not compatible with spontaneous ventilation in a supine position, or requires an oral airway.\n* Congenital heart disease or history of dysrhythmia.\n* Taking digoxin or beta-blocker\n* Anxiolytic medication is ordered before the MRI (e.g., midazolam or ketamine).\n* History or a family (parent or sibling) history of malignant hyperthermia.\n* Allergy to or has a contraindication to propofol, lidocaine, or dexmedetomidine.\n* Tracheostomy or other mechanical airway device present\n* Received within the past 12 hours an oral or intravenous alpha-adrenergic, beta-adrenergic agonist, or antagonist drugs (e.g., clonidine, propranolol, albuterol).\n* Patient is not scheduled to receive anesthesia-sedation care or is noted to \"try-without anesthesia\" for the MRI\n* Patient has significant developmental or psychological delays\n* Patient scheduled for scan of duration \\\u003C30 minutes or \\>90 minutes",{"count":564,"type":22},105,[60],"The most common imaging procedure requiring sedation\u002Fanesthesia for the pediatric population is magnetic resonance imaging (MRI). However, the optimal anesthetic\u002Fsedation plan has not been determined for these procedures. Historically, common medications have included the use of pentobarbital and propofol, but in 2015, publication in the New England Journal of Medicine highlighted the accumulating evidence for the possible neurotoxic effects of these types of anesthetics in animal models and a collection of epidemiologic studies in humans. Although these initial possibilities have since been proven as less of a concern, in the interim, data has shown that alternative sedative agents, such as dexmedetomidine, may not have the same neurotoxic effect and could possibly even provide neuroprotection. Dexmedetomidine also possesses other beneficial traits such as reducing risks of pulmonary atelectasis or upper airway collapse, typically found with the administration of propofol.\n\nA concern raised by previous studies has been the possibility that the addition of dexmedetomidine could increase recovery times, leading to disruptions in workflow. Although it has been shown that large doses of dexmedetomidine exposure may lead to longer PACU stays, it is uncertain whether a small dose of dexmedetomidine would have such a significant impact. Based on the investigators' pilot trial6, the investigators found that a bolus of 1 mcg\u002Fkg dose of dexmedetomidine with a bolus of titrated propofol of 2-3 mg\u002Fkg and an infusion of propofol of 100 mcg\u002Fkg\u002Fmin provided adequate sedation for successful scans, reduced propofol (infusion) exposure by 60%, and did not significantly increase recovery times.\n\nFinally, there is a paucity in literature for studies examining a range of doses subsequently; often, a control group is compared to a single, self-selected dose of choice. Here, the investigators hope to provide a range of doses to minimize selection bias in our study design and determine the dose that would provide the optimal sedation for these scans and minimize excess anesthetic exposure.",[568,569,570,571,572,573],"MRI Sedation","Pediatric Sedation","Propofol Dosage","Emergence Delirium, Anesthesia","Recovery Time","Dexmedetomidine",[575,576,577,578,579],"pediatrics","sedation","dexmedetomidine","propofol","MRI","2026-05-27",{"date":582,"type":40},"2026-05-29",{"date":584,"type":22},"2026-06",{"date":586,"type":22},"2028-03",{"name":46,"class":47},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":18,"minAge":594,"maxAge":196,"enrollmentInfo":595,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":97},"100607124","assessment-of-microvascular-circulation-in-the-pediatric-cardiac-surgery-patient-100607124","NCT07184476","Assessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient","Inclusion Criteria:\n\n* All patients with primary diagnosis of ventricular septal defect or tetrology of Fallot\n\nExclusion Criteria:\n\n* Critical airway, congenital genetic abnormality of the mouth\u002Ftongue","1 Day",{"count":596,"type":22},40,"The pediatric cardiac surgery patient endures a tremendous number of physiologic alterations during surgery and cardiopulmonary bypass (CPB) that lasts well into the recovery period. Most of the hemodynamic data are assessed and treated with macrovascular assessment tools such as blood pressure and central venous line measures. Studies show there may be an incoherence of macrovascular to microvascular assessment; i.e. a patient with a stable macrovascular status may not be in the state of microvascular stability. The use of a handheld device called Cytocam incident dark-field (IDF) microcirculatory camera (Braedius Medical, Huizen, Netherlands) gives real-time video screening and data feedback to assess the microvasculature in the hemodynamically labile patient.",[599],"Tetrology of Fallot","2026-05-26",{"date":602,"type":40},"2026-05-28",{"date":604,"type":40},"2026-03-18",{"date":606,"type":22},"2027-03-17",{"name":46,"class":47},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":18,"minAge":145,"maxAge":615,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":617,"briefSummary":618,"conditions":619,"keywords":621,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":97},"100599662","striae-distensae-treatment-using-deep-skin-abrasion-100599662","NCT07087405","Striae Distensae Treatment Using Deep Skin Abrasion","Stretch Mark Treatment Using Subcutaneous Skin Abrasion","Inclusion Criteria:\n\n* Striae distensae\n\nExclusion Criteria:\n\n* Smoking\n* coagulation deficiency","70 Years",{"count":423,"type":22},[25],"The goal of this clinical trial is to learn if a device works to treat striae distensae. It will also learn about the safety of the device. The main questions it aims to answer are:\n\n1. Does the device improve the appearance of striae distensae?\n2. Does the device cause any problems when treating striae distensae? Researchers will compare the appearance of striae distensae before and after treatment with the device.\n\nParticipants will:\n\n1. Undergo treatment with the device in the clinic\n2. Visit the clinic 1 week, 3 months, and 1 year for checkups and tests",[620],"Striae Distensae",[620],{"date":602,"type":40},{"date":624,"type":40},"2025-10-01",{"date":626,"type":22},"2026-12-01",{"name":46,"class":47},{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":18,"minAge":634,"maxAge":635,"enrollmentInfo":636,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":97},"100397498","mechanisms-of-increased-disease-severity-in-ad-patients-with-the-il-4ra-r576-polymorphism-100397498","NCT04455906","Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism","Inclusion Criteria:\n\n1. Male or female participants ≥6 to 65 yrs of age\n2. Meet AD Standard Diagnostic Criteria\n\nExclusion Criteria:\n\n1. Enrollment in another clinical trial\n2. Hypersensitivity to an agent used for the skin decolonization protocol\n3. Use within 4 weeks of systemic treatment with immunosuppressive\u002Fimmunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)\n4. Phototherapy for AD within 4 weeks\n5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks\n6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days\n7. Bleach baths within 7 days of the first Visit\n8. Use of oral or topical antibiotics within 21 days of the beginning of the study\n9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids\n10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy\n11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,\n12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.\n13. Febrile illness at time of visits\n14. Suspected immune deficiency or family history of primary immunodeficiency","6 Years","65 Years",{"count":637,"type":22},111,"This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.",[640],"Atopic Dermatitis","2026-05-15",{"date":643,"type":40},"2026-05-18",{"date":645,"type":40},"2020-11-30",{"date":647,"type":22},"2027-09-15",{"name":46,"class":47},{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":656,"conditions":657,"keywords":661,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":670,"locationsCount":97},"100229949","using-microbial-genomics-to-elucidate-the-source-of-central-line-associated-bloodstream-infections-100229949","NCT02271243","Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections","Inclusion Criteria:\n\n* Hospitalized at Boston Children's Hospital\n* Central venous catheter of any type including peripherally inserted central catheters (PICC) in any location.\n* Laboratory-confirmed bloodstream infection (LCBI) diagnosed by a clinical blood culture growing certain Gram-negative rods\n\nExclusion Criteria:\n\n* Patients with CDC-defined secondary bloodstream infections",{"count":21,"type":22},"Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.",[658,659,660],"Laboratory-confirmed Bloodstream Infection","Central Line-associated Bloodstream Infections","Mucosal Barrier Injury",[662,663,664],"Central line-associated bloodstream infections","mucosal barrier injury","laboratory-confirmed bloodstream infection","2026-05-13",{"date":641,"type":40},{"date":668,"type":40},"2014-11",{"date":259,"type":22},{"name":46,"class":47},""]